ELGX up +2.51% percent Today $ELGX High is at 12.2
Post# of 42
Recent News posted below.
Endologix Inc ELGX other info.
http://investorshangout.com/Endologix-Inc-ELGX-53997/
ELGX Endologix Inc Recent Headline News
Endologix Completes Patient Enrollment in the Nellix(R) EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Nov 18, 6:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the Company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System" for the endovascular repair of infrarenal abdominal aortic aneurysms ("AAA" . Primary endpoint analysis results at one-year and beyond will be used to support the Company's premarket approval (PMA) application to the U.S. Food & Drug Administration (FDA) for the Nellix EVAS System.
ELGX: 12.24 (+0.31)
Post Earnings Update: Endologix Has Climbed 2.1% Higher in Past 2 Weeks (ELGX)
Comtex SmarTrend(R) - Mon Nov 17, 4:01PM CST
18 days ago, on October 30th, 2014, Endologix (NASDAQ:ELGX) reported its earnings. Analysts, on average, expected a loss of $0.13 per share on sales of $37.0 million. Endologix actually reported a loss of $0.13 per share on sales of $37.2 million, beating EPS estimates by $0.00 and matching revenue estimates. Shares of Endologix have climbed from $11.24 to $11.48, representing a gain of 2.1% since the company reported earnings 18 days ago.
ELGX: 12.24 (+0.31)
Endologix to Participate in Three Investor Conferences in November
GlobeNewswire - Thu Nov 06, 4:17PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at three investor conferences in November. The first conference is the Stephens 2014 Fall Conference in New York, NY.
ELGX: 12.24 (+0.31)
InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST
VR: 40.94 (+0.45), JBHT: 80.04 (+0.11), FCX: 28.09 (-0.10), BBY: 36.05 (+1.15), NS: 59.10 (-0.70), LL: 56.38 (+2.61), ELGX: 12.24 (+0.31), ENFC: 13.91 (+0.13), RCL: 70.19 (+0.37), LMCA: 35.88 (-0.39), SPW: 92.37 (-0.41), OPK: 8.17 (-0.06), BIOL: 2.43 (+0.05), IMI: 2.25 (-0.03), NHF: 11.13 (-0.20), SIX: 40.10 (-0.70), TWTR: 39.79 (-0.82), SCHW: 28.51 (-0.25)
Endologix to Host Investor Meeting on Thursday, November 20, 2014
GlobeNewswire - Mon Nov 03, 8:36AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2014 investor meeting, which will be held on November 20, 2014 from 5:00 to 7:30 pm ET at the New York Hilton Midtown. The event will include a Company update, presentations from prominent physicians and a question and answer session with the physicians and Endologix management
ELGX: 12.24 (+0.31)
More on Endologix Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 4:01PM CDT
ELGX: 12.24 (+0.31)
Endologix meets 3Q profit forecasts
Automated Insights - Fri Oct 31, 4:03AM CDT
IRVINE, Calif. (AP) _ Endologix Inc. (ELGX) on Friday reported a third-quarter loss of $13.9 million.
ELGX: 12.24 (+0.31)
Endologix's (ELGX) CEO John McDermott on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:54PM CDT
ELGX: 12.24 (+0.31)
Endologix EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:02PM CDT
ELGX: 12.24 (+0.31)
Endologix (ELGX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT
ELGX: 12.24 (+0.31)
Endologix Reports 12% Global Revenue Growth for the Third Quarter 2014
GlobeNewswire - Thu Oct 30, 3:50PM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2014.
ELGX: 12.24 (+0.31)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT
ELLI: 40.55 (-0.50), AIV: 36.63 (-0.34), EPAY: 24.94 (-0.54), CPSI: 60.49 (-0.20), LNKD: 220.86 (-0.21), ADNC: 3.59 (-0.01), CODE: 21.08 (-0.21), HME: 62.32 (-0.80), ESIO: 6.85 (-0.15), HIL: 3.77 (-0.03), DGI: 27.02 (+0.57), AHT: 10.09 (unch), COLM: 43.53 (+1.88), AHS: 16.35 (+0.09), CSLT: 11.16 (+0.06), FRT: 131.64 (-0.49), DGII: 7.38 (+0.01), ADUS: 21.51 (-0.44), ESS: 198.74 (-2.47), EXPE: 87.76 (-0.61), IMPV: 41.90 (-0.63), CCI: 80.73 (+0.21), CPT: 75.04 (-0.52), GB: 48.86 (-0.87), AEGR: 21.10 (+0.61), ATEN: 4.12 (-0.06), ELGX: 12.24 (+0.31), AFFX: 8.74 (-0.84), CHE: 109.04 (+1.69), BCOV: 6.59 (-0.19), DCT: 33.31 (-0.49), ELX: 5.41 (unch), GNMK: 11.16 (-0.22), AXTI: 2.50 (+0.05), INT: 44.37 (+0.38), EGN: 66.25 (-0.31), EGO: 6.47 (-0.13), GMED: 22.61 (-0.29), GDOT: 22.26 (+0.18), KEG: 2.29 (-0.12), ISBC: 10.71 (-0.06), GRPN: 7.40 (+0.03), ALJ: 15.73 (+0.08), CTRL: 15.22 (-0.11), GPRO: 82.85 (-1.25), EMN: 84.99 (-0.50), IMMR: 8.78 (-0.19), CUBE: 20.85 (-0.28), BYI: 82.89 (+0.10), ATRC: 17.29 (-0.66), BYD: 11.69 (-0.05), FLDM: 30.46 (-0.47), BEAT: 8.14 (-0.33), FLR: 66.39 (+0.45), FLT: 147.25 (-1.06), EHTH: 23.33 (+0.52)
Endologix to Report Third Quarter 2014 Financial Results on October 30, 2014
GlobeNewswire - Thu Oct 09, 8:36AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2014 financial results, which will take place on Thursday October 30, 2014 after the close of the market.
ELGX: 12.24 (+0.31)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.55 (+0.10), ECYT: 6.41 (+0.03), PDFS: 13.41 (-0.32), CTCM: 5.90 (+0.02), WRES: 3.00 (+0.01), ADHD: 3.25 (+0.01), RTRX: 8.49 (-0.54), GWGH: 9.15 (unch), MTEX: 22.30 (+0.63), ELGX: 12.24 (+0.31), DWSN: 15.47 (-0.20), OTIC: 21.93 (-1.06), THRM: 39.98 (-0.54)
Nasdaq stocks posting largest volume increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PDFS: 13.41 (-0.32), IKAN: 0.33 (+0.01), SANW: 3.47 (-0.13), TIBX: 23.69 (+0.01), ALIM: 5.54 (-0.15), MOVE: 20.95 (-0.03), SPEX: 1.62 (+0.02), MBTF: 4.80 (-0.06), ELGX: 12.24 (+0.31), SMPL: 16.25 (-0.09)
Endologix (ELGX) Crumbles: Stock Plunges by 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:48AM CDT
Endologix stock fell over 18% last trading session, continuing its recent downtrend
ABC: 89.10 (-0.66), LH: 101.22 (+0.04), ELGX: 12.24 (+0.31), COO: 166.91 (-3.24)
Market Maker Surveillance Report. ELGX, PGP, USNZY, NETE, TNXP, ADHD, Losing Stocks With Lowest Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:43AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Endologix Inc (NASDAQ:ELGX), PIMCO Global Stocksplus and Income Fund (NYSE GP), Usinas Siderurgicas de Minas Gerais SA Usiminas (OTC:USNZY), NET ELEMENT INC (OTC:NETE), Tonix Pharmaceuticals Holding Corp (OTC:TNXP), (NASDAQ:ADHD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.34 (-0.01), PGP: 20.53 (+0.25), TNXP: 7.07 (-0.04), ADHD: 3.25 (+0.01), ELGX: 12.24 (+0.31)
Why Endologix (ELGX) Stock Reached A New Low Today
at The Street - Mon Sep 29, 11:25AM CDT
Endologix (ELGX) shares fell to a new 2014 low on Monday after the company lowered its full year revenue guidance.
ELGX: 12.24 (+0.31)
Endologix Announces Preliminary Third Quarter 2014 Revenue and Updates Financial Guidance
GlobeNewswire - Mon Sep 29, 6:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the third quarter ended September 30, 2014. Endologix anticipates third quarter 2014 global revenue of approximately $37.0 million, representing approximately 11% growth as compared to $33.3 million for the third quarter 2013.
ELGX: 12.24 (+0.31)